Skip to main content
Clinical Trials/NCT02421861
NCT02421861TerminatedPhase 2

Critical Care Anxiety and Long-Term Outcomes Management

University of Washington0 sites10 target enrollmentStarted: April 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Terminated
Enrollment
10
Primary Endpoint
Anxiety (Visual Analog Scale for Anxiety (VAS-A)

Study Overview

Brief Summary

The aims of this study are to (1) test the benefits of a non-pharmacologic anxiety management approach with patients who are critically ill and/or traumatically injured during intensive care hospitalization and (2) test whether this approach reduces anxiety and improves engagement in rehabilitation therapies, shortens duration of hospitalization, and improves psychological and quality of life outcomes.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years or older
  • •Ability to read, write, and speak English
  • •Alert (Best RASS ICU sedation score ≥-2)
  • •Current CAM-ICU test negative
  • •Expected ICU stay ≥48 hours
  • •Anxiety Visual Analog Scale (VAS-A) score ≥30
  • •Prescribed rehabilitation therapy at eligibility

Exclusion Criteria

  • •Inability to communicate (verbally, or via hand writing/gestures)
  • •Greater than 90% probability of mortality in hospital
  • •Anticipated discharge to hospice or transition to end-of-life care
  • •Pre-existing cognitive impairment (e.g., dementia, pervasive developmental disorder)

Arms & Interventions

Anxiety Management (AM)

Experimental

Intervention: Anxiety Management in the ICU (Behavioral)

Usual Care (UC)

Placebo Comparator

Intervention: Usual Care (UC) (Other)

Outcomes

Primary Outcomes

Anxiety (Visual Analog Scale for Anxiety (VAS-A)

Time Frame: Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 days

Anxiety at discharge and change in anxiety from baseline to discharge as measured by the Visual Analog Scale for Anxiety (VAS-A)

Secondary Outcomes

  • Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)(3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS))
  • Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)(3 months after enrollment as measured by the PCL-5)
  • Length of ICU and Hospital Stay(Measured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days))
  • Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)(As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days))
  • Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36)(3 months after enrollment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jennifer Jutte

Assistant Professor

University of Washington

Similar Trials